Form 6-K NEOVASC INC For: Feb 15

 

 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

 

 

For the month of		February		2017
Commission File Number		001-36458

 

Neovasc Inc.

(Translation of registrant’s name into English)

Suite 5138 – 13562 Maycrest Way Richmond, British Columbia, Canada V6V 2J7

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

Form 20-F

Form 40-F

X

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):          

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):           

 

 

DOCUMENTS INCLUDED AS PART OF THIS REPORT

 

 

Document
1		News Release dated February 15, 2017 - Neovasc to Present at the Leerink Partners Global Healthcare Conference

 

 

 

Document 1

 

 

NEWS RELEASE

 

Neovasc to Present at the Leerink Partners Global Healthcare Conference

 

NASDAQ: NVCN

TSX: NVC

 

Vancouver, BC, Canada – February 15, 2017 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVC) today announced that Alexei Marko, chief executive officer, is scheduled to present at the LEERINK Partners 6^th Annual Global Healthcare Conference on Thursday, February 16^th at 9:00 am ET at the Lotte New York Palace in New York City.

A live audio webcast of the presentation will be available on the Investors page of Neovasc’s website at www.neovasc.com.

About Neovasc Inc.

Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace.  Its products include the Neovasc Reducer™, for the treatment of refractory angina which is not currently available in the U.S. and has been available in Europe since 2015 and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under investigation in the U.S., Canada and Europe. The Company also sells a line of advanced biological tissue products that are used as key components in third-party medical products including transcatheter heart valves. For more information, visit: www.neovasc.com.

 

Investor Relations

Neovasc Inc.

Chris Clark

604 248-4138

[email protected]

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Neovasc Inc.
	(Registrant)
Date:          February 15, 2017	By:	/s/ Chris Clark
		Name:	Chris Clark
		Title:	Chief Financial Officer

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Adams Diversified Equity Fund Declares Distribution and Announces First Quarter Performance
• Adams Natural Resources Fund Declares Distribution and Announces First Quarter Performance
• La Jolla Institute for Immunology and RevolKa started a Research Collaboration